STABLE LIQUID VACCINIA VIRUS FORMULATIONS
    21.
    发明申请

    公开(公告)号:US20170326230A1

    公开(公告)日:2017-11-16

    申请号:US15529668

    申请日:2015-12-01

    申请人: TRANSGENE SA

    发明人: Mélina CHASLE

    摘要: The present invention relates to liquid formulations of poxvirus, in particular vaccinia virus, stable during storage. Such stable liquid formulations comprise a) a poxvirus, preferably a vaccinia virus, b) a pharmaceutically acceptable buffer, c) a monovalent salt, d) a pharmaceutically acceptable disaccharide or sugar alcohol, and e) a pharmaceutically acceptable chelating agent, wherein the pH of the formulation is comprised between 6.5 and 8.5.

    POXVIRUS-PLASMODIUM RECOMBINANTS, COMPOSITIONS CONTAINING SUCH RECOMBINANTS, USES THEREOF, AND METHODS OF MAKING AND USING SAME
    26.
    发明申请
    POXVIRUS-PLASMODIUM RECOMBINANTS, COMPOSITIONS CONTAINING SUCH RECOMBINANTS, USES THEREOF, AND METHODS OF MAKING AND USING SAME 审中-公开
    POXVIRUS-PLASMODIUM重组体,包含这些重组体的组合物,其用途及其制备方法和使用方法

    公开(公告)号:US20150191704A1

    公开(公告)日:2015-07-09

    申请号:US14576578

    申请日:2014-12-19

    IPC分类号: C12N7/00 A61K39/275

    摘要: The invention provides a recombinant or synthetic or engineered or non-naturally occurring poxvirus that contains and expresses DNA encoding a heterologous or exogenous antigen, epitope or immunogen and Flagellin or an operable binding portion thereof. The poxvirus can contain or be engineered to contain and express vaccinia host range gene K1L. The poxvirus can be attenuated as to mammals, e.g., NYVAC, NYVAC.1, NYVAC.2, avipox, canarypox, fowlpox, ALVAC, TROVAC, MVA, or MVA-BN. The invention also provides methods for inducing an immunological response involving the poxvirus, and compositions containing the poxvirus. The antigen, epitope or immunogen that the poxvirus expresses can be at least one Plasmodium antigen. The Plasmodium antigen(s), epitope(s) or immunogen(s) can be SERA, ABRA, Pfhsp70, AMA-1, Pfs25, Pfs16, CSP, PfSSP2, LSA-1 repeatless, MSA-1, AMA-1 or combination(s) thereof. Advantageously the poxvirus contains DNA coding for and expresses Plasmodium antigen(s) CSP, PfSSP2, LSA-1-repeatless, MSA-1, SERA, AMA-1 and Pfs25. Also, advantageously, the poxvirus is a NYVAC poxvirus. The invention thus also provides an anti-malarial immunogenic or immunological compositions comprising the poxvirus, and methods for inducing an immunogenic or immunological response against malaria or Plasmodium in a mammal comprising administering to the mammal the poxvirus or an immunological or immunogenic composition containing the poxvirus. The mammal can be a human.

    摘要翻译: 本发明提供重组或合成或工程化或非天然存在的痘病毒,其含有和表达编码异源或外源抗原,表位或免疫原和鞭毛蛋白或其可操作结合部分的DNA。 痘病毒可以包含或被设计成含有和表达痘苗宿主范围基因K1L。 痘病毒可以减毒哺乳动物,例如NYVAC,NYVAC.1,NYVAC.2,avipox,金丝雀,禽痘,ALVAC,TROVAC,MVA或MVA-BN。 本发明还提供诱导涉及痘病毒的免疫应答的方法和含有痘病毒的组合物。 痘病毒表达的抗原,表位或免疫原可以是至少一种疟原虫抗原。 疟原虫抗原,表位或免疫原可以是SERA,ABRA,Pfhsp70,AMA-1,Pfs25,Pfs16,CSP,PfSSP2,LSA-1无重复,MSA-1,AMA-1或组合 (s)。 有利的是,痘病毒含有编码并表达疟原虫抗原CSP,PfSSP2,LSA-1-无重复,MSA-1,SERA,AMA-1和Pfs25的DNA。 此外,有利地,痘病毒是NYVAC痘病毒。 因此,本发明还提供了包含痘病毒的抗疟疾免疫原性或免疫组合物,以及用于在哺乳动物中诱导针对疟疾或疟原虫的免疫原性或免疫应答的方法,包括向哺乳动物施用痘病毒或含有痘病毒的免疫或免疫原性组合物。 哺乳动物可以是一个人。

    Nucleic acid molecules and polypeptides for immune modulation
    30.
    发明授权
    Nucleic acid molecules and polypeptides for immune modulation 有权
    用于免疫调节的核酸分子和多肽

    公开(公告)号:US08268331B2

    公开(公告)日:2012-09-18

    申请号:US12437426

    申请日:2009-05-07

    摘要: The invention provides gp38 polypeptides, which play a role in immunomodulation, nucleic acid molecules encoding these polypeptides, and therapeutic and diagnostic methods employing these polypeptides and nucleic acid molecules. The invention also provides methods for identifying compounds that modulate the biological activities of gp38 nucleic acid molecules and polypeptides, and therapeutic methods employing these compounds.

    摘要翻译: 本发明提供了在免疫调节中起作用的gp38多肽,编码这些多肽的核酸分子,以及使用这些多肽和核酸分子的治疗和诊断方法。 本发明还提供鉴定调节gp38核酸分子和多肽的生物学活性的化合物的方法,以及使用这些化合物的治疗方法。